Semax
Studied for: focus & clarity
Semax is a synthetic fragment derived from ACTH, modified so it carries no corticotropic activity. Research examines its role in mental clarity, focus, and cognitive resilience.
Last reviewed September 26, 2026
How it is thought to work
Research investigates Semax for its influence on brain-derived neurotrophic factor expression and on the dopaminergic and serotonergic systems associated with attention.
- Neurotrophic SupportStudied for a role in BDNF signaling, associated with neural adaptability and resilience.
- Attention PathwaysExplored in research on focus and sustained attention, without the hormonal activity of its parent sequence.
- Route studied
- Subcutaneous
- Research status
- Early clinical
Semax has been examined in animal models of stroke and spinal cord injury and in small human studies, including a clinical trial in patients with ischemic stroke and brain network imaging research, but large-scale trial data are not available.
Research
What the research covers
What research examines
- Recovery after experimental ischemic stroke in rats
- Outcomes in patients at different stages of ischemic stroke
- BDNF and neurotrophic signaling
- Brain network activity, including the default mode network
- Functional recovery after spinal cord injury in mice
- Attention and focus pathways
Reported effects in studies
- Human safety data are limited
- Adverse events are not summarized in the cited studies
- Described as an ACTH-derived fragment modified to lack corticotropic activity
- Long-term safety has not been established in large controlled trials
Studied range
What research protocols have used
Research protocols have used 1–2 mg per administration, once daily (morning), in 4-week blocks with 4 weeks off.
For research use only. These figures summarize published research protocols. They are not instructions or medical advice.
Every CoreX order ships with a per-lot protocol guide.
Open the reconstitution calculatorRelated compounds
Researched alongside
- SelankSelank is a synthetic analog of the immunomodulatory peptide tuftsin. Research examines its role in emotional balance and stress modulation, and its profile as a non-sedating anxiolytic candidate.Read profile$89
- NAD+NAD+ is a coenzyme central to how cells convert fuel into usable energy. Research examines its role in redox reactions, mitochondrial output, and the repair pathways associated with biological aging.Read profile$99
Studies
Cited research
- [The efficacy of semax in the tretament of patients at different stages of ischemic stroke].
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2018 · Clinical trial · PMID 29798983
- The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis.
BMC genomics · 2014 · PMID 24661604
- ACTH-like Peptides Compensate Rat Brain Gene Expression Profile Disrupted by Ischemia a Day After Experimental Stroke.
Biomedicines · 2024 · PMID 39767736
- Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice.
British journal of pharmacology · 2025 · PMID 40692165
- Effects of Semax on the Default Mode Network of the Brain.
Bulletin of experimental biology and medicine · 2018 · PMID 30225715
FAQ
Questions about Semax
Semax is a synthetic peptide derived from a fragment of adrenocorticotropic hormone (ACTH), described in the literature as a synthetic analog of ACTH(4-10). It has been modified so that it does not carry the corticotropic, or hormone-releasing, activity of its parent sequence. Research has examined Semax in the context of mental clarity, focus, cognitive resilience and neuroprotection, including animal models of stroke and spinal cord injury.
Research has investigated Semax for its influence on brain-derived neurotrophic factor (BDNF) expression, a signaling pathway associated with neural adaptability and resilience. It has also been studied in relation to dopaminergic and serotonergic systems linked to attention. Genome-wide studies in rats with focal brain ischemia reported changes in the expression of genes related to immune and vascular systems, and one mouse study linked its effects after spinal cord injury to the μ opioid receptor gene Oprm1.
Published work has examined Semax in rat models of experimental stroke, where ACTH-like peptides were reported to shift brain gene expression profiles disrupted by ischemia. A clinical trial evaluated Semax in patients at different stages of ischemic stroke. Imaging studies have explored its effects on the brain's default mode network and functional connectivity, and a 2025 mouse study examined functional recovery after spinal cord injury. Early evidence is promising but not definitive.
Human safety data on Semax are limited, and adverse events are not summarized in the cited studies. The peptide is described as a modified ACTH fragment lacking corticotropic activity, meaning it is not expected to act on the hormonal pathways of its parent sequence, but this has not been confirmed through large, long-term controlled trials. Much of the available research comes from animal models and relatively small human studies.
Research protocols have used 1–2 mg per administration by the subcutaneous route, once daily in the morning, in 4-week blocks followed by 4 weeks off. These figures describe what research protocols have used and are not a recommendation. Each CoreX order ships with a protocol guide for laboratory reference. Semax is supplied for laboratory research use only.
Ask about Semax
Plain answers from our library: the science, the studied ranges and our products. It can be wrong, and it does not give medical advice.
AI answers can be wrong. Research use only.
Compare
Related comparisons
- Semax vs SelankSemax and Selank are synthetic peptides studied in cognition research, but they derive from different parent molecules. Semax is a fragment of ACTH modified to carry no corticotropic activity, while Selank is an analog of the immunomodulatory peptide tuftsin. Research on Semax centers on brain-derived neurotrophic factor expression and dopaminergic and serotonergic systems linked to attention. Selank has been investigated for influence on GABAergic signaling, BDNF expression, and serotonin metabolism. Semax has been studied in animal models of stroke and spinal cord injury and in small human studies, including ischemic stroke patients. Selank has been studied mainly in cell and rodent stress models, with a small randomized controlled trial on anxiety disorders. Human safety data for both are limited.